Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment.
Teplizumab delayed progression from stage 2 to stage 3 type 1 diabetes by 32.5 months
Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment.
Diabetic ketoacidosis (diabetic ketoacidosis) remains a preventable yet frequent complication at the onset of type 1 diabetes (T1D) in children, driven by delayed symptom recognition, socioeconomic disparities, and inconsistent access to care.
A narrative review was conducted using PubMed, EMBASE, Scopus, Web of Science, and Google Scholar (2011-2026).
Extended follow-up showed clinical diabetes onset delayed by a median of 32.5 months.
Diabetic ketoacidosis risk is influenced by younger age, socioeconomic disadvantage, rural residence, misdiagnosis, and limited access to specialized care.
Sustained public awareness and community-based education reduce diabetic ketoacidosis incidence, whereas short-term campaigns show transient effects.
Structured screening programs, including TrialNet and TEDDY, demonstrate near-elimination of diabetic ketoacidosis among monitored children.
It is approved for individuals with stage 2 T1D aged ≥ 1 year and has recently gained approval for selected patients with newly diagnosed T1D, expanding opportunities for early disease modification.
Reducing diabetic ketoacidosis at T1D onset requires integrated, sustained strategies combining public awareness, systematic autoantibody screening, structured follow-up, and access to emerging immunotherapies.
Coordinated care across primary providers, pediatric endocrinologists, and research networks is essential to advance a proactive, prevention-oriented model of pediatric T1D care.